
Quarterly report 2023-Q3
added 11-13-2023
Sientra Net Income 2011-2026 | SIEN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Sientra
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -62.5 M | -89.9 M | -107 M | -82.6 M | -64 M | -40.2 M | -41.2 M | -5.81 M | -19.1 M | -23.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.81 M | -107 M | -53.6 M |
Quarterly Net Income Sientra
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.8 M | -9.48 M | -12.9 M | - | -15 M | -18.3 M | -18 M | - | 28.4 M | -20.1 M | -54.7 M | -21.2 M | -5.82 M | -34.3 M | -28.6 M | -20.2 M | -22.4 M | -37.7 M | -26.5 M | -24.6 M | -20.5 M | -18 M | -19.4 M | -17.8 M | -14.4 M | -20.4 M | -11.4 M | -8.07 M | -9.96 M | -10.2 M | -11.9 M | -28.2 M | -6.6 M | -2.99 M | -3.38 M | -3.2 M | -1.45 M | -160 K | -1 M | -3.08 M | -6.48 M | -5.46 M | -4.11 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.4 M | -54.7 M | -14.3 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
-19 M | $ 3.28 | - | $ 123 M | ||
|
Electromed
ELMD
|
7.54 M | $ 25.74 | - | $ 218 M | ||
|
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | ||
|
Globus Medical
GMED
|
538 M | $ 90.74 | - | $ 12.3 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | ||
|
Helius Medical Technologies
HSDT
|
-8.85 M | $ 2.08 | - | $ 1.26 M | ||
|
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | ||
|
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 13.38 | - | $ 1.81 B | ||
|
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | ||
|
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | ||
|
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | ||
|
Pulmonx Corporation
LUNG
|
-54 M | $ 1.23 | - | $ 50 M | ||
|
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | ||
|
Orthofix Medical
OFIX
|
-92.2 M | $ 11.91 | - | $ 472 M | ||
|
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
247 M | $ 182.87 | - | $ 12.9 B | ||
|
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.6 | -1.96 % | $ 37.3 M | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.15 | - | $ 5.96 M | ||
|
ClearPoint Neuro
CLPT
|
-25.5 M | $ 11.08 | - | $ 314 M | ||
|
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | ||
|
Stryker Corporation
SYK
|
849 M | $ 321.43 | -0.02 % | $ 123 B | ||
|
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | ||
|
Tactile Systems Technology
TCMD
|
19.1 M | $ 23.57 | - | $ 539 M | ||
|
TELA Bio
TELA
|
-38.8 M | $ 0.78 | - | $ 36.6 M | ||
|
Second Sight Medical Products
EYES
|
-26.6 M | - | -0.97 % | $ 54.4 M | ||
|
TransMedics Group
TMDX
|
190 M | $ 101.26 | - | $ 3.44 B | ||
|
Tandem Diabetes Care
TNDM
|
-589 K | $ 18.63 | - | $ 1.27 B | ||
|
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | ||
|
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M | ||
|
Varex Imaging Corporation
VREX
|
-70.3 M | $ 12.07 | - | $ 500 M | ||
|
Butterfly Network
BFLY
|
-72.5 M | $ 5.16 | - | $ 1.09 B | ||
|
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | ||
|
Vivos Therapeutics
VVOS
|
-21.2 M | $ 0.85 | - | $ 8.73 M | ||
|
Beyond Air
XAIR
|
-46.6 M | $ 0.51 | - | $ 34.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 15.14 | - | $ 355 M | ||
|
Delcath Systems
DCTH
|
2.7 M | $ 10.55 | - | $ 378 M | ||
|
Xtant Medical Holdings
XTNT
|
4.97 M | $ 0.55 | -1.78 % | $ 76.7 M | ||
|
Zimmer Biomet Holdings
ZBH
|
904 M | $ 82.8 | - | $ 16.8 B | ||
|
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.04 | - | $ 17.6 M | ||
|
CONMED Corporation
CNMD
|
47.1 M | $ 36.79 | - | $ 1.14 B |